Ashfield Capital Partners LLC decreased its position in GlaxoSmithKline PLC (NYSE:GSK) by 6.3% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 31,568 shares of the pharmaceutical company’s stock after selling 2,136 shares during the period. Ashfield Capital Partners LLC’s holdings in GlaxoSmithKline PLC were worth $1,282,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the business. FMR LLC increased its stake in GlaxoSmithKline PLC by 5.9% in the 2nd quarter. FMR LLC now owns 25,024,276 shares of the pharmaceutical company’s stock valued at $1,079,047,000 after buying an additional 1,389,238 shares during the last quarter. Fisher Asset Management LLC increased its stake in GlaxoSmithKline PLC by 2.3% in the 3rd quarter. Fisher Asset Management LLC now owns 12,828,251 shares of the pharmaceutical company’s stock valued at $520,827,000 after buying an additional 293,866 shares during the last quarter. Renaissance Technologies LLC increased its stake in GlaxoSmithKline PLC by 112.1% in the 2nd quarter. Renaissance Technologies LLC now owns 9,338,000 shares of the pharmaceutical company’s stock valued at $402,655,000 after buying an additional 4,935,900 shares during the last quarter. Hotchkis & Wiley Capital Management LLC increased its stake in GlaxoSmithKline PLC by 4.3% in the 2nd quarter. Hotchkis & Wiley Capital Management LLC now owns 7,847,327 shares of the pharmaceutical company’s stock valued at $338,377,000 after buying an additional 322,700 shares during the last quarter. Finally, Federated Investors Inc. PA increased its stake in GlaxoSmithKline PLC by 22.7% in the 2nd quarter. Federated Investors Inc. PA now owns 4,511,155 shares of the pharmaceutical company’s stock valued at $194,521,000 after buying an additional 833,501 shares during the last quarter. Hedge funds and other institutional investors own 9.32% of the company’s stock.

GlaxoSmithKline PLC (GSK) traded down $0.10 on Thursday, reaching $34.88. 4,245,700 shares of the company traded hands, compared to its average volume of 3,440,653. The company has a market cap of $85,360.00, a P/E ratio of 12.40, a PEG ratio of 1.94 and a beta of 1.00. GlaxoSmithKline PLC has a 52 week low of $34.72 and a 52 week high of $44.53. The company has a debt-to-equity ratio of 2.96, a quick ratio of 0.44 and a current ratio of 0.64.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 11th. Investors of record on Friday, November 10th will be issued a $0.5037 dividend. The ex-dividend date of this dividend is Thursday, November 9th. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.49. This represents a $2.01 annualized dividend and a yield of 5.78%. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is 159.20%.

ILLEGAL ACTIVITY WARNING: “Ashfield Capital Partners LLC Has $1.28 Million Holdings in GlaxoSmithKline PLC (GSK)” was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/11/16/ashfield-capital-partners-llc-has-1-28-million-holdings-in-glaxosmithkline-plc-gsk.html.

GSK has been the subject of several analyst reports. Zacks Investment Research lowered shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research note on Tuesday, October 24th. Morgan Stanley lowered shares of GlaxoSmithKline PLC from an “equal weight” rating to an “underweight” rating in a research note on Friday, September 8th. BidaskClub raised shares of GlaxoSmithKline PLC from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. Argus reissued a “buy” rating and set a $50.00 target price on shares of GlaxoSmithKline PLC in a research report on Thursday, August 31st. Finally, TheStreet raised shares of GlaxoSmithKline PLC from a “c+” rating to a “b” rating in a research report on Wednesday, October 25th. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and five have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $44.33.

In other GlaxoSmithKline PLC news, major shareholder Plc Glaxosmithkline acquired 428,571 shares of the business’s stock in a transaction that occurred on Monday, November 6th. The stock was bought at an average cost of $14.00 per share, with a total value of $5,999,994.00. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 10.00% of the stock is currently owned by company insiders.

GlaxoSmithKline PLC Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.